Evidence map›Paper›PMID 34266985›Full record

ArticleThe Journal of rheumatology2021

Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis.

Kimberly Showalter, Aileen Hoffmann, Carrie Richardson, David Aaby, Jungwha Lee, Jane Dematte, Rishi Agrawal, Hatice Savas, Xiaoping Wu, Rowland W Chang and 1 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kimberly ShowalterK. Showalter, MD, Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago, Illinois, and Hospital for Special Surgery, Department of Medicine, Division of Rheumatology, New York, New York.ORCID 0000-0001-9343-5545
Aileen HoffmannA. Hoffmann, MS, Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Rheumatology, Chicago, Illinois.
Carrie RichardsonC. Richardson, MD, Northwestern University Feinberg School of Medicine, Department of Medicine, Chicago, Illinois.
David AabyD. Aaby, MS, Northwestern University Feinberg School of Medicine, Department of Preventive Medicine, Chicago, Illinois.
Jungwha LeeJ. Lee, PhD, MPH, Northwestern University Feinberg School of Medicine, Department of Preventive Medicine, and Institute for Public Health and Medicine, Chicago, Illinois.
Jane DematteJ. Dematte, MD, MBA, Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Chicago, Illinois.
Rishi AgrawalR. Agrawal, MD, H. Savas, MD, Northwestern University Feinberg School of Medicine, Department of Radiology, Chicago, Illinois.
Hatice SavasR. Agrawal, MD, H. Savas, MD, Northwestern University Feinberg School of Medicine, Department of Radiology, Chicago, Illinois.
Xiaoping WuX. Wu, MD, MS, New York Presbyterian/Weill Cornell, Department of Medicine, Division of Pulmonary and Critical Care Medicine, New York, New York.
Rowland W ChangR.W. Chang, MD, MPH, Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Rheumatology, Department of Preventive Medicine, and Institute for Public Health and Medicine, Chicago, Illinois.
Monique HinchcliffM. Hinchcliff, MD, MS, Northwestern University Feinberg School of Medicine, Department of Medicine, Division of Rheumatology, Chicago, Illinois, and Yale School of Medicine, Department of Medicine, Section of Rheumatology, Allergy & Immunology, New Haven, Connecticut, USA. monique.hinchcliff@yale.edu.ORCID 0000-0002-8652-9890
Northwestern University · USCornell University · US

Funding

Multidisciplinary Clinical and Translational Science (MCTS) Program (UL1)UL1TR000150 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LLOYD-JONES, DONALD M · 2012 to 2013
$10.1M
Resource CoreP30AR072579 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI NAN E ROTHROCK · 2017 to 2026
$8.3M
Northwestern University Clinical and Translational Science Institute (NUCATS)KL2TR001424 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SHARMA, LEENA · 2015 to 2023
$8.1M
Physical Activity Changes & Thersholds: Quality of Life and Outcomes in Knee OAP60AR064464 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SHARMA, LEENA · 2013 to 2017
$4.5M
Pathogenic Wnt-beta catenin target genes in macrophages and fibrosisR01AR073270 · NIAMS · YALE UNIVERSITY · PI HINCHCLIFF, MONIQUE EVANGELINE · 2019 to 2023
$2.6M
Predictive Ability of Gene Expression Signatures In Skin as SSc BiomarkersK23AR059763 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HINCHCLIFF, MONIQUE EVANGELINE · 2013 to 2015
$390k
NCATS NIH HHS KL2 TR001424NCATS NIH HHS UL1 TR000150NIAMS NIH HHS K23 AR059763NIAMS NIH HHS P30 AR072579NIAMS NIH HHS P60 AR064464NIAMS NIH HHS R01 AR073270
6 · The paper itself

Abstract

objectiveTo identify clinical factors, including esophageal dilation on chest high-resolution computed tomography (HRCT), that are associated with pulmonary function decline in patients with systemic sclerosis (SSc).

methodsPatients fulfilled 2013 SSc criteria and had ≥ 1 HRCT and ≥ 2 pulmonary function tests (PFTs). According to published methods, widest esophageal diameter (WED) and radiographic interstitial lung disease (ILD) were assessed, and WED was dichotomized as dilated (≥ 19 mm) vs not dilated (< 19 mm). Clinically meaningful PFT decline was defined as % predicted change in forced vital capacity (FVC) ≥ 5 and/or diffusion capacity for carbon monoxide (DLCO) ≥ 15. Linear mixed effects models were used to model PFT change over time.

resultsOne hundred thirty-eight patients with SSc met the study criteria: 100 (72%) had radiographic ILD; 49 (35%) demonstrated FVC decline (median follow-up 2.9 yrs). Patients with antitopoisomerase I (Scl-70) autoantibodies had 5-year FVC% predicted decline (-6.33, 95% CI -9.87 to -2.79), whereas patients without Scl-70 demonstrated 5-year FVC stability (+1.78, 95% CI -0.59 to 4.15). Esophageal diameter did not distinguish between those with vs without FVC decline. Patients with esophageal dilation had statistically significant 5-year DLCO% predicted decline (-5.58, 95% CI -10.00 to -1.15), but this decline was unlikely clinically significant. Similar results were observed in the subanalysis of patients with radiographic ILD.

conclusionIn patients with SSc, Scl-70 positivity is a risk factor for FVC% predicted decline at 5 years. Esophageal dilation on HRCT was associated with a minimal, nonclinically significant decline in DLCO and no change in FVC during the 5-year follow-up. These results have prognostic implications for SSc-ILD patients with esophageal dilation.

Indexed as

Lung Diseases, InterstitialScleroderma, SystemicDilatationHumansLungVital Capacitybiomarkersgastrointestinal diseaseinterstitial lung diseasesystemic sclerosis

Identifiers

PMID34266985
PMCPMC8985598
OpenAlexW3181992362

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.